Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology discussed the SABCS abstract – Tucatinib versus placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status.
– New analyses from the pivotal HER2CLIMB analysis identify the hormone receptor status outcomes –
BOTHELL, Wash.—(BUSINESS WIRE)—Seagen Inc. (Nasdaq: SGEN) today announced at the San Antonio Breast Cancer Symposium (SABCS) Virtual Symposium, held December 8-11, 2020, the presentation of new data from TUKYSA (tucatinib), its HER2-positive metastatic breast cancer treatment. Nine abstracts, including two spotlight posters, illustrate the dedication of the organization to tackling unmet breast cancer needs.
Highlights of the meeting’s main data presentations include:
Efficacy Outcomes from the HER2CLIMB Trial by Hormone Receptor Status
The outcome of the pivotal HER2CLIMB hormone receptor (HR) status trial for TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer will be featured in the spotlight poster (Abstract #PD3-08). Erika P. Hamilton, M.D., Director of the Breast Cancer and Gynecologic Cancer Research Program at the Sarah Cannon Research Institute, will be presenting the findings.
The addition of TUKYSA to trastuzumab and capecitabine, as previously reported, resulted in clinically important improvements compared to placebo in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). The recent exploratory studies presented at SABCS have shown that changes in PFS, OS, and ORR with TUKYSA have been consistently observed across subgroups of hormone receptor status, including in brain metastasis patients.
Seagen Medicines and Pipeline Agents SABCS 2020 Data Presentations:
Presentation information relating to TUKYSA and the SABCS investigational agent ladiratuzumab vedotin is presented below. They can find written abstracts here. On December 9, 2020, poster presentations will be available.